![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Sunday, July 30, 2023 3:51:06 PM
Michael J. Ambrogi has been appointed as Vice President - Senior Technology Fellow of the Company effective 9/1/2020. He has been our Chief Operating Officer since 2010 and previously served as our U.S. General Manager from 2006 to 2010. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing, service and human resources activities worldwide.
Asaf Danziger has served as Chief Executive Officer of Novocure since 2002 and has been a director of Novocure since 2012. Mr. Danziger has led the company and the development of TTFields therapy from preclinical testing through regulatory approvals to commercial sales in Europe and the United States.
Charles G. Phillips III has been a director of Novocure since 2012 and has served on our audit committee and as the chairperson of our compensation committee since 2012.
Mr. Doyle has served as our Executive Chairman since 2016, as Chairman of the Board since 2009 and as a member of our Board of Directors since 2004.
Dr. Eilon Kirson joined Novocure in 2002 and served as Chief Medical Officer until 2012 when he was promoted to Chief Science Officer and Head of Research and Development.
Dr. Ely Benaim joined Novocure in April 2019 and serves as Chief Medical Officer.
Frank Leonard has served as Novocure’s Chief Development Officer since September 2020. This newly created executive role has responsibility for engineering, product development, business development, and the overall strategic and operational leadership of Novocure’s innovation platforms.
Gabriel Leung has been Vice Chairman and a director of Novocure since 2011.
Todd Longsworth joined Novocure in 2012 and serves as General Counsel.
Wilco Groenhuysen has served as Novocure’s Chief Operating Officer since September 2020. He is responsible for the general and administrative management of the company, the strategic and operational leadership of Novocure’s supply chain, warehousing and distribution, quality assurance and information technology operations. Mr. Groenhuysen is tasked to ensure organizational readiness in anticipation of the completion of four phase 3 clinical trials over the next few years.
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/zdnysAmbrogi_NVCR.png)
https://investorshub.advfn.com/uimage/uploads/2023/7/30/iqylhAsaf_Danziger_NVCR.png
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/zvvrpCharles_Phillips_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/vhkosDoyle_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/cqjzsEilon_Kirson_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/hgnxtEly_Benaim_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/jrbezFrank_Leonard_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/aoylbGabriel_Leung_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/nwivnTodd_Longsworth_NVCR.png)
![](http://investorshub.advfn.com/uimage/uploads/2023/7/30/gpqbsWilhelmus_Groenhuysen_NVCR.png)
Recent NVCR News
- Novocure to Report Second Quarter 2024 Financial Results • Business Wire • 07/01/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:09:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:37:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 10:13:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/06/2024 09:43:31 PM
- METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival • Business Wire • 06/03/2024 12:00:00 PM
- TIGER-Studie berichtet über neue Überlebensergebnisse der TTFields-Therapie bei neu diagnostizierten Glioblastom-Patienten in Deutschland • Business Wire • 05/24/2024 01:06:00 PM
- TIGER Study Reports New TTFields Therapy Survival Results for Newly Diagnosed Glioblastoma Patients in Germany • Business Wire • 05/23/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2024 12:01:17 PM
- Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon • Business Wire • 05/02/2024 11:01:00 AM
- Novocure Reports First Quarter 2024 Financial Results • Business Wire • 05/02/2024 11:00:00 AM
- Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024 • Business Wire • 04/24/2024 02:45:00 PM
- Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024 • Business Wire • 04/05/2024 11:00:00 AM
- Novocure to Report First Quarter 2024 Financial Results • Business Wire • 04/01/2024 11:00:00 AM
- METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長 • Business Wire • 03/29/2024 12:07:00 AM
- Klinische Phase-3-Studie METIS erreicht primären Endpunkt und zeigt eine statistisch signifikante Verlängerung der Zeit bis zur intrakraniellen Progression bei Patient:innen mit Hirnmetastasen von nicht-kleinzelligem Lungenkrebs • Business Wire • 03/28/2024 05:51:00 PM
- L’essai clinique de phase 3 METIS a atteint son critère principal, démontrant un allongement statistiquement significatif du délai médian jusqu’à la progression intracrânienne chez les patients porteurs de métastases cérébrales consécutives.. • Business Wire • 03/28/2024 05:50:00 PM
- METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer • Business Wire • 03/27/2024 11:00:00 AM
- INNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGO • Business Wire • 03/11/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:08:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:39:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 10:56:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:06:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 10:01:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:43:29 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM